Log in

T2014-001 (Temsirolimus)

Protocol Opened: 3-17-2015

Study Contacts

 

CURRENT STUDY DOCUMENTS

Current T2014-001 Protocol 01-18-2018 (Amendment #2) T2014-001 Protocol 01-18-2018 (Amendment #2)
T2014-001 Protocol 01-18-2018 Tracked (Amendment #2) T2014-001 Protocol 01-18-2018 Tracked (Amendment #2)
Current T2014-001 Sample Consent 01-18-2018 (Amendment #2) T2014-001 Sample Consent 01-18-2018 (Amendment #2)
T2014-001 Sample Consent 01-18-2018 Tracked (Amendment #2) T2014-001 Sample Consent 01-18-2018 Tracked (Amendment #2)
Amendment #2 Cover Letter 01-18-2018 Amendment #2 Cover Letter 01-18-2018
T2014-001 Investigator Acknowledgment Page - Amendment #1 T2014-001 Investigator Acknowledgment Page - Amendment #2
T2014-001 Research Monitoring Plan T2014-001 Research Monitoring Plan
IND Exemption Letter 11-7-2014 IND Exemption Letter 11-7-2014

Aug 2017 Investigator Brochure

Aug 2017 IB Summary of Changes

Aug 2017 Password

Aug 2017 Investigator Brochure

Aug 2017 IB Summary of Changes

Aug 2017 IB Password

July 2017 Package Insert  July 2017 Package Insert

 

STUDY DOCUMENT ARCHIVE

T2014-001 Protocol 12-18-2014 Original T2014-001 Protocol 12-18-2014
T2014-001 Sample Consent 12-18-2014 Original T2014-001 Sample Consent 12-18-2014
Protocol Correspondence
Amendments
Enrollment & Drug Ordering
CRFs and Roadmaps
Adverse Events and DLT
Correlative Studies
Data Safety Monitoring and Progress Reports